Katherine H. Walker

Katherine H. Walker

Auto-generated profile, based on publicly available information

Katherine H. Walker

Department of Medicine, Brigham and Women’s Hospital, Boston

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
HSHo Pan Sham
Ho Pan Sham
KWKatherine H. Walker
Katherine H. Walker
RARaja-Elie E Abdulnour
Raja-Elie E Abdulnour
NKNandini Krishnamoorthy
Nandini Krishnamoorthy
DDDavid N. Douda
David N. Douda
BLBruce Levy
Bruce Levy
Specialized proresolving mediators (SPMs) decrease NF-κB activity to prevent excessive tissue damage and promote the resolution of acute inflammation. Mechanisms for NF-κB regulation by SPMs remain to be determined. In this study, after LPS challenge, the SPMs 15-epi-lipoxin A4 (15-epi-LXA4), resolvin D1, resolvin D2, resolvin D3, and 17-epi-resolvin D1 were produced in vivo in murine lungs. In LPS-activated human bronchial epithelial cells, select SPMs increased expression of the NF-κB regulators A20 and single Ig IL-1R–related molecule (SIGIRR). Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor–dependent manner in epithelial cells and in murine pneumonia. This SPM regulated NF-κB–induced cytokines to decrease pathogen-mediated inflammation. In addition to dampening lung inflammation, surprisingly, 15-epi-LXA4 also enhanced pathogen clearance with increased antimicrobial peptide expression. Taken together, to our knowledge these results are the first to identify endogenous agonists for A20 and SIGIRR expression to regulate NF-κB activity and to establish mechanisms for NF-κB regulation by SPMs for pneumonia resolution.

3 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NKNandini Krishnamoorthy
Nandini Krishnamoorthy
KWKatherine H. Walker
Katherine H. Walker
TBThayse R. Brüggemann
Thayse R. Brüggemann
LTLuciana P. Tavares
Luciana P. Tavares
ESEthan W. Smith
Ethan W. Smith
BLBruce Levy
Bruce Levy
The resolution of infection is an active process with specific molecular and cellular mechanisms that temper inflammation and enhance pathogen clearance. Here, the specialized pro-resolving mediator (SPM) Maresin 1 (MaR1) inhibited respiratory syncytial virus (RSV)-induced inflammation. inlerleukin-13 production from type 2 innate lymphoid cells (ILC) and CD4 T helper type 2 cells was decreased by exogenous MaR1. In addition, MaR1 increased amphiregulin production and decreased RSV viral transcripts to promote resolution. MaR1 also promoted interferon-β production in mouse lung tissues and also in pediatric lung slices. MaR1 significantly inhibited the RSV-triggered aberrant inflammatory phenotype in FoxP3-expressing Tregs. The receptor for MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was constitutively expressed on Tregs. Following RSV infection, mice lacking Lgr6 had exacerbated type 2 immune responses with an increased viral burden and blunted responses to MaR1. Together, these findings have uncovered a multi-pronged protective signaling axis for MaR1–Lgr6, improving Tregs’s suppressive function and upregulating host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimately promoting restoration of airway mucosal homeostasis.

8 July 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDMelody G. Duvall
Melody G. Duvall
MFMary E Fuhlbrigge
Mary E Fuhlbrigge
RRRoisin B. Reilly
Roisin B. Reilly
KWKatherine H. Walker
Katherine H. Walker
AKAyşe Kılıç
Ayşe Kılıç
BLBruce Levy
Bruce Levy
NK cells provide immune surveillance and host protection against viruses and tumors through their cytotoxic effector function. Cytoskeletal rearrangement is necessary for NK cell lytic granule trafficking and immune synapse formation to trigger apoptosis of targeted cells. LIM kinase (LIMK) regulates F-actin remodeling by phosphorylating cofilin to inhibit actin severing and depolymerization. In this study, in human NK cells, the glucocorticoid dexamethasone downregulated LIMK expression, F-actin accumulation at the immune synapse, lytic granule trafficking, and cytotoxicity. In contrast, the specialized proresolving mediator lipoxin A4 promoted NK cell LIMK expression, lytic granule polarization to the immune synapse and cytotoxicity. Using a LIMK inhibitor, we show that LIMK activity is necessary for NK cell cytotoxicity, including lipoxin A4’s proresolving actions. Together, our findings identify LIMK as an important control mechanism for NK cell cytoskeletal rearrangement that is differentially regulated by glucocorticoids and specialized proresolving mediators to influence NK cell cytotoxicity.

1 August 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
CCC. Lee Cohen
C. Lee Cohen
KWKatherine H. Walker
Katherine H. Walker
MHMina Hsiang
Mina Hsiang
PSPaul D. Sonenthal
Paul D. Sonenthal
ERElisabeth D. Riviello
Elisabeth D. Riviello
EKEdy Y. Kim
Edy Y. Kim
The speed and scale of new information during the COVID-19 pandemic required a new approach toward developing best practices and evidence-based clinical guidance. To address this need, we produced COVIDProtocols.org, a collaborative, evidence-based, digital platform for the development and dissemination of COVID-19 clinical guidelines that has been used by over 500,000 people from 196 countries. We use a Collaborative Writing Application (CWA) to facilitate an expedited expert review process and a web platform that deploys content directly from the CWA to minimize any delays. Over 200 contributors have volunteered to create open creative-commons content that spans over 30 specialties and medical disciplines. Multiple local and national governments, hospitals, and clinics have used the site as a key resource for their own clinical guideline development. COVIDprotocols.org represents a model for efficiently launching open-access clinical guidelines during crisis situations to share expertise and combat misinformation.

27 September 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
JKJames S. Krinsley
James S. Krinsley
KWKatherine H. Walker
Katherine H. Walker
LZLilian Zerihun
Lilian Zerihun
FIFarwa Ilyas
Farwa Ilyas
AEAyara Ehinmisan
Ayara Ehinmisan
JPJean-Charles Preiser
Jean-Charles Preiser

24 June 2026 in CHEST Critical Care
Verified
Journal Article
Open access
KWKatherine H. Walker
Katherine H. Walker
VLValencia Lambert
Valencia Lambert
EMEmanuele Mazzola
Emanuele Mazzola
ADAlexa DiPalma
Alexa DiPalma
EREmily B. Rubin
Emily B. Rubin
JLJoshua R. Lakin
Joshua R. Lakin